Loading...
menu
Search
Features
Markets
News
Resources
Pricing
Home
Stock
APLMW
APLMW News & Events
-
Add to Watchlist
Trade APLMW
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Stock Price Prediction
Technical
Valuation
Financials
Earnings
Should I Buy
News & Events
APLMW News
Apollomics Confirms Ongoing Nasdaq Listing After Hearing Cancellation
Oct 15 2025
Newsfilter
Nasdaq Suspends Trading of Apollomics Inc., Ltd.
Sep 17 2025
Globenewswire
Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress
Apr 03 2025
Newsfilter
Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib
Mar 31 2025
Newsfilter
Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Dec 20 2024
Newsfilter
Apollomics Regains Compliance with Nasdaq's Minimum Bid Price Requirement
Dec 10 2024
Newsfilter
Apollomics' Announces Shareholder Approval and Effective Date for 1-for-100 Reverse Share Split
Nov 21 2024
Newsfilter
Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress
Aug 14 2024
Newsfilter
Show More News
APLMW Events
No data
APLMW Monitor News
No data
APLMW Earnings Analysis
No Data
People Also Watch
